131 related articles for article (PubMed ID: 29506490)
1. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype analysis of ocular findings in Rubinstein-Taybi syndrome - A case report and review of literature.
Jin E; Le H; Jewell A; Couser NL
Ophthalmic Genet; 2024 Feb; 45(1):51-58. PubMed ID: 37017262
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and genetic characteristics of 21 children with Rubinstein-Taybi syndrome].
Yang SH; Liu HR; Li JY; Zhang Y; Liu ZQ; Wang L; Chen XL; Shangguan SF
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):351-356. PubMed ID: 38527506
[No Abstract] [Full Text] [Related]
4. Molecular insight into CREBBP and TANGO2 variants causing intellectual disability.
Hussain SI; Muhammad N; Khan N; Khan M; Fardous F; Tahir R; Yasin M; Khan SA; Saleha S; Muhammad N; Wasif N; Khan S
J Gene Med; 2024 Jan; 26(1):e3591. PubMed ID: 37721116
[TBL] [Abstract][Full Text] [Related]
5. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.
de Thonel A; Ahlskog JK; Daupin K; Dubreuil V; Berthelet J; Chaput C; Pires G; Leonetti C; Abane R; Barris LC; Leray I; Aalto AL; Naceri S; Cordonnier M; Benasolo C; Sanial M; Duchateau A; Vihervaara A; Puustinen MC; Miozzo F; Fergelot P; Lebigot É; Verloes A; Gressens P; Lacombe D; Gobbo J; Garrido C; Westerheide SD; David L; Petitjean M; Taboureau O; Rodrigues-Lima F; Passemard S; Sabéran-Djoneidi D; Nguyen L; Lancaster M; Sistonen L; Mezger V
Nat Commun; 2022 Nov; 13(1):7002. PubMed ID: 36385105
[TBL] [Abstract][Full Text] [Related]
6. Dermatological findings in Rubinstein-Taybi Syndrome.
Cammarata-Scalisi F; Diociaiuti A; Cárdenas Tadich A; Sandoval X; Oranges T; Filippeschi C; Araya Castillo M; Willoughby CE; Cerri A; Gervasini C; Callea M
Ital J Dermatol Venerol; 2023 Aug; 158(4):316-320. PubMed ID: 37282850
[TBL] [Abstract][Full Text] [Related]
7. Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.
Van Gils J; Magdinier F; Fergelot P; Lacombe D
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202860
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement.
Lacombe D; Bloch-Zupan A; Bredrup C; Cooper EB; Houge SD; García-Miñaúr S; Kayserili H; Larizza L; Lopez Gonzalez V; Menke LA; Milani D; Saettini F; Stevens CA; Tooke L; Van der Zee JA; Van Genderen MM; Van-Gils J; Waite J; Adrien JL; Bartsch O; Bitoun P; Bouts AHM; Cueto-González AM; Dominguez-Garrido E; Duijkers FA; Fergelot P; Halstead E; Huisman SA; Meossi C; Mullins J; Nikkel SM; Oliver C; Prada E; Rei A; Riddle I; Rodriguez-Fonseca C; Rodríguez Pena R; Russell J; Saba A; Santos-Simarro F; Simpson BN; Smith DF; Stevens MF; Szakszon K; Taupiac E; Totaro N; Valenzuena Palafoll I; Van Der Kaay DCM; Van Wijk MP; Vyshka K; Wiley S; Hennekam RC
J Med Genet; 2024 May; 61(6):503-519. PubMed ID: 38471765
[TBL] [Abstract][Full Text] [Related]
9. EP300 facilitates human trophoblast stem cell differentiation.
van Voorden AJ; Keijser R; Veenboer GJM; Lopes Cardozo SA; Diek D; Vlaardingerbroek JA; van Dijk M; Ris-Stalpers C; van Pelt AMM; Afink GB
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2217405120. PubMed ID: 37406095
[TBL] [Abstract][Full Text] [Related]
10. Congenital glaucoma as a presenting feature of Rubinstein-Taybi syndrome in an infant with a novel pathogenic variant in the
Snehi S; Kaur A; Chaudhry C; Kaushik S
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36653044
[TBL] [Abstract][Full Text] [Related]
11. Generation of an induced pluripotent stem cell line IGIBi18-A from an Indian patient with Rubinstein Taybi Syndrome.
Verma S; Dalabehera S; Maurya R; Singh D; Prasher B; Pandey R; Bapat S; Ramalingam S; Sachidanandan C
Stem Cell Res; 2024 May; 78():103456. PubMed ID: 38820863
[TBL] [Abstract][Full Text] [Related]
12. The relationship between neurodevelopmental transcriptional programs and insomnia: From Rubinstein-Taybi syndrome into energy metabolism.
Cunha L; Paschalidis M; Moysés-Oliveira M; Marquezini BP; Deconto TB; Guerreiro P; Kloster A; Mosini AC; Gallego Adami LN; Andersen ML; Tufik S
Sleep Med; 2023 Dec; 112():9-11. PubMed ID: 37801861
[TBL] [Abstract][Full Text] [Related]
13. NRF1 association with AUTS2-Polycomb mediates specific gene activation in the brain.
Liu S; Aldinger KA; Cheng CV; Kiyama T; Dave M; McNamara HK; Zhao W; Stafford JM; Descostes N; Lee P; Caraffi SG; Ivanovski I; Errichiello E; Zweier C; Zuffardi O; Schneider M; Papavasiliou AS; Perry MS; Humberson J; Cho MT; Weber A; Swale A; Badea TC; Mao CA; Garavelli L; Dobyns WB; Reinberg D
Mol Cell; 2021 Nov; 81(22):4663-4676.e8. PubMed ID: 34637754
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Rubinstein-Taybi Syndrome Presenting with Extensive Keloid Formation and Review of Literature.
Kim JW; Ko JM; Lee DY; Shin JW
Ann Dermatol; 2023 May; 35(Suppl 1):S19-S24. PubMed ID: 37853858
[TBL] [Abstract][Full Text] [Related]
15. Menke-Hennekam syndrome; delineation of domain-specific subtypes with distinct clinical and DNA methylation profiles.
Haghshenas S; Bout HJ; Schijns JM; Levy MA; Kerkhof J; Bhai P; McConkey H; Jenkins ZA; Williams EM; Halliday BJ; Huisman SA; Lauffer P; de Waard V; Witteveen L; Banka S; Brady AF; Galazzi E; van Gils J; Hurst ACE; Kaiser FJ; Lacombe D; Martinez-Monseny AF; Fergelot P; Monteiro FP; Parenti I; Persani L; Santos-Simarro F; Simpson BN; ; Alders M; Robertson SP; Sadikovic B; Menke LA
HGG Adv; 2024 Mar; 5(3):100287. PubMed ID: 38553851
[TBL] [Abstract][Full Text] [Related]
16. Identification of 22q11.2 deletion in a patient with schizophrenia and clinically diagnosed Rubinstein-Taybi syndrome.
Nagai Y; Nishioka M; Tanaka T; Shimano T; Kirino E; Suzuki T; Kato T
PCN Rep; 2022 Sep; 1(3):e34. PubMed ID: 38868697
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with
Qualls D; Noy A; Straus D; Matasar M; Moskowitz C; Seshan V; Dogan A; Salles G; Younes A; Zelenetz AD; Batlevi CL
Leuk Lymphoma; 2023 Mar; 64(3):738-741. PubMed ID: 36642966
[No Abstract] [Full Text] [Related]
18. Characterization of a novel HDAC2 pathogenetic variant: a missing puzzle piece for chromatinopathies.
Di Fede E; Lettieri A; Taci E; Castiglioni S; Rebellato S; Parodi C; Colombo EA; Grazioli P; Natacci F; Marchisio P; Pezzani L; Fazio G; Milani D; Massa V; Gervasini C
Hum Genet; 2024 May; ():. PubMed ID: 38753158
[TBL] [Abstract][Full Text] [Related]
19. Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors.
Crawford MC; Tripu DR; Barritt SA; Jing Y; Gallimore D; Kales SC; Bhanu NV; Xiong Y; Fang Y; Butler KAT; LeClair CA; Coussens NP; Simeonov A; Garcia BA; Dibble CC; Meier JL
ACS Chem Biol; 2023 Oct; 18(10):2249-2258. PubMed ID: 37737090
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
